News for Sartorius Stedim Biotech S.A. (56S1.F)

Sartorius Stedim Biotech, a leading partner of the biopharma industry, recorded exceptionally strong growth in 2020 that was driven by strong organic development, several acquisitions and additional momentum from business related to the coronavirus pandemic. According to preliminary figures, the Group closed the year with significant double-digit growth rates in sales revenue, order intake and earnings, recording further gains across all geographies.

AUBAGNE, France, Jan. 27, 2021 /PRNewswire/ -- Sartorius Stedim Biotech, a leading partner of the biopharma industry, recorded exceptionally strong growth ...

France stocks lower at close of trade; CAC 40 down 1.63%

France stocks lower at close of trade; CAC 40 down 0.71%

Sartorius Stedim Biotech SA Sartorius Stedim Biotech SA: DECLARATION RELATIVE AU NOMBRE D'ACTIONS ET DE DROITS DE VOTE COMPOSANT LE CAPITAL SOCIAL 04-Jan-2021 / 11:13 CET/CEST Information... | January 4, 2021